Dr. OlgaBezzubova

Olga Bezzubova is the leader of the Munich IP Practice and the Firm's European life sciences and chemistry patent prosecution group. She has extensive experience in obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics.

Olga advises on all aspects of patent prosecution and opposition, SPCs (supplementary protection certificates), patent validity, and infringement. She has successfully handled dozens of European oppositions on the patentee's and the opponent's side for companies such as BMS/Celgene, Merck, Puma, and Akebia Therapeutics in the fields of small and large molecules, including antibodies, ADCs (antibody drug conjugates), and CAR-Ts (chimeric antigen receptor T cells). Olga has represented clients in highly competitive areas of RNA (ribonucleic acid) interference (RNAi) and CRISPR/Cas gene editing (clustered regularly interspaced short palindromic repeats), was involved in invalidity and infringement proceedings related to amino acid production, and obtained SPCs for the first approved gene therapy of SMA (spinal muscular atrophy). She has experience in developing global IP strategies for established biotech companies and start-ups, as well as managing patent portfolios worldwide. Olga's unique background in physics and biology allows her to counsel clients in matters involving various aspects of cell biology, genomics, proteomics, molecular biology, food science, biopharmaceuticals, and biophysics, as well as emerging technologies at the convergence of biological and physical sciences.

Olga has authored and coauthored numerous publications in the field of molecular genetics and IP.